Arcadia Biosciences (RKDA) Cash & Equivalents (2014 - 2026)

Arcadia Biosciences (RKDA) has 12 years of Cash & Equivalents data on file, last reported at $300000.0 in Q4 2025.

• Quarterly Cash & Equivalents fell 92.93% year-over-year to $300000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $300000.0 (down 92.93% YoY) and the FY2025 annual result came in at $300000.0, down 92.93% from the prior year.
• Cash & Equivalents declined to $300000.0 in Q4 2025, from $1.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $44.0 million in Q2 2021 to a low of $300000.0 in Q4 2025.
• A 5-year average of $15.3 million and a median of $12.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 340.55% — and 2025, when it plunged 92.93%.
• Tracing RKDA's Cash & Equivalents over 5 years: stood at $28.7 million in 2021, then dropped by 28.03% to $20.6 million in 2022, then slumped by 68.43% to $6.5 million in 2023, then plunged by 34.92% to $4.2 million in 2024, then sank by 92.93% to $300000.0 in 2025.
• The last three Cash & Equivalents figures came in at $300000.0 (Q4 2025), $1.1 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.